These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20230766)

  • 21. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mood disorders: regulation by metabotropic glutamate receptors.
    Pilc A; Chaki S; Nowak G; Witkin JM
    Biochem Pharmacol; 2008 Mar; 75(5):997-1006. PubMed ID: 18164691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major depression: emerging therapeutics.
    Sen S; Sanacora G
    Mt Sinai J Med; 2008; 75(3):204-25. PubMed ID: 18704976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The involvement of glutamate in the pathophysiology of depression.
    Palucha A; Pilc A
    Drug News Perspect; 2005 May; 18(4):262-8. PubMed ID: 16034483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopaminergic-based pharmacotherapies for depression.
    Papakostas GI
    Eur Neuropsychopharmacol; 2006 Aug; 16(6):391-402. PubMed ID: 16413172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The P11, tPA/plasminogen system and brain-derived neurotrophic factor: Implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants.
    Tsai SJ
    Med Hypotheses; 2007; 68(1):180-3. PubMed ID: 16890384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
    McIntyre RS; Muzina DJ; Adams A; Lourenco MT; Law CW; Soczynska JK; Woldeyohannes HO; Nathanson J; Kennedy SH
    Expert Opin Pharmacother; 2009 Dec; 10(18):3061-75. PubMed ID: 19954275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior.
    Schmidt HD; Duman RS
    Behav Pharmacol; 2007 Sep; 18(5-6):391-418. PubMed ID: 17762509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiating antidepressants of the future: efficacy and safety.
    Rosenzweig-Lipson S; Beyer CE; Hughes ZA; Khawaja X; Rajarao SJ; Malberg JE; Rahman Z; Ring RH; Schechter LE
    Pharmacol Ther; 2007 Jan; 113(1):134-53. PubMed ID: 17010443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of beta-endorphin in the pathophysiology of major depression.
    Hegadoren KM; O'Donnell T; Lanius R; Coupland NJ; Lacaze-Masmonteil N
    Neuropeptides; 2009 Oct; 43(5):341-53. PubMed ID: 19647870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stress responsive neurohormones in depression and anxiety.
    Ströhle A; Holsboer F
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.
    Baghai TC; Volz HP; Möller HJ
    World J Biol Psychiatry; 2006; 7(4):198-222. PubMed ID: 17071541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New perspectives on glutamate receptor antagonists as antidepressants.
    Chung C
    Arch Pharm Res; 2012 Mar; 35(4):573-7. PubMed ID: 22553049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
    Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
    Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory mechanisms in major depressive disorder.
    Raedler TJ
    Curr Opin Psychiatry; 2011 Nov; 24(6):519-25. PubMed ID: 21897249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.